Group items tagged

The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Research supported by the Division of Materials Research (DMR) focuses on advancing fundamental understanding of materials, materials discovery, design, synthesis, characterization, properties, and materials-related phenomena. DMR awards enable understanding of the electronic, atomic, and molecular structures, mechanisms, and processes that govern nanoscale to macroscale morphology and properties; manipulation and control of these properties; discovery of emerging phenomena of matter

The Taking Flight Award seeks to promote the careers of young epilepsy investigators, enabling them to develop a research focus independent of their mentor(s). In 2018, CURE will issue one request for proposals for the Taking Flight Award. Please refer to the LOI guidelines for an overview of CURE's 2018 priority areas, application instructions and FAQs. Eligibility You must fall into one of the following categories to be eligible for the Taking Flight Award: A senior postdoctoral fellow who has a minimum of 3 years postdoctoral experience A clinical fellow who is a Neurology Resident in his/her Neurology training and considering Epilepsy Fellowships Newly appointed faculty within one year of having completed postdoctoral training

The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Model systems using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA.

To date, the pursuit of disease-modifying therapy development for Alzheimer's disease (AD) has been primarily informed by the study of diseased individuals, often by comparing genomic and other molecular, cellular and physiologic features in AD cases and controls. This has proven extremely challenging given the disease's heterogeneity and its multifactorial etiology. There is a growing appreciation that the development of effective treatment and prevention for complex diseases such as AD can benefit from gaining a much deeper understanding of what it means to be well and which genomic, epigenomic, environmental, social, and behavioral factors promote wellness and protection against disease.

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders.

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). Also listed under U01.

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research.

The McKnight Endowment Fund for Neuroscience supports innovative research designed to bring science closer to the day when diseases of the brain can be accurately diagnosed, prevented, and treated. To that end, the McKnight Endowment Fund for Neuroscience invites Letters of Intent for its 2018 McKnight Technological Innovations in Neuroscience awards. The program encourages and supports scientists working on the development of novel and creative approaches to the understanding of brain function. McKnight is interested in how a new technology may be used to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. Because the program seeks to advance and enlarge the range of technologies available to the neurosciences, research based primarily on existing techniques will not be considered. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited.

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to autism spectrum disorders. The proposed training must be scientifically linked to autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills & planning, epilepsy, sleep, repetitive disorders), neurobiology (anatomy, development, neuroimaging), pharmacology, neuropathology, genetics, epigenetics, genomics, epigenomics, immunology, molecular and cellular mechanisms, studies employing model organisms and systems, and studies of treatment and service delivery. Special consideration will be given to projects focused on gender issues in autism. This includes studies examining the female protective effect, neurobiological and neuroanatomical examination of the female autism brain, diagnostic differences and challenges in females, the female phenotype, and health and lifespan issues, including vocational services and employment. ASF also invites studies focused on unaffected siblings and recurrence risk in the offspring of unaffected siblings. ASF is also interested in supporting research on the neurobiology and molecular biology of autism using post-mortem brain tissue. The one-year awards include $25,000 for predoctoral and medical students and $35,000 for postdoctoral students.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.

This solicitation extends the Collaborative Research in Computational Neuroscience program for three years. Proposals for collaborations involving Japan are now supported through a new partnership with the National Institute of Information and Communications Technology. Please see the proposal preparation instructions and country-specific instructions and limitations in Sections V and VIII of this solicitation, and the companion documents published by CRCNS partner agencies referenced in Section VIII. The description of scientific topics and approaches has been updated in Section II of this solicitation. Agency contacts have been updated in Section VIII. Results from prior NSF, NIH, and/or CRCNS support must be included in the Project Description if any PI or co-PI identified on the project has received NSF funding, NIH funding, or CRCNS funding from another participating agency, with a start date in the past five years.

The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells are essential to understanding the etiology of AD.

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients.

Epidemiological studies have shown that psychiatric disorders, constitute a significant public health burden across diverse populations worldwide. These mental disorders are characterized by marked genetic heterogeneity, with both common and rare variation contributing to the complex phenotypic outcomes. For reasons such as population homogeneity and ease of ascertainment, most genome-wide genetic studies to date have mainly focused on cohorts of European-ancestry, however, no single population is sufficient to fully uncover the variants underlying neuropsychiatric diseases in all populations. The absence of diverse ancestries in genome-wide association studies has therefore negatively impacted their ability to illuminate the full genetic architecture of complex neuropsychiatric traits. Populations with different ancestral origins vary in terms of allele frequencies, biological adaptations, and other properties that affect the detectability and importance of risk variants. Lack of ancestrally diverse genome-wide data can lead to the misidentification of causal variants due to cryptic population stratification or simply overlooking a causal variant altogether, since rare variants are likely to be more recent in origin and more geographically localized.